Zug, Switzerland

Covagen Ag


USPTO Granted Patents = 7

% Expired Patents = 71.4



Forward Citations = 9

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal Dragan Grabulovski (7 out of 13 patents)

silverMedal Julian Bertschinger (7 out of 8 patents)

bronzeMedal Patricia Henne (3 out of 4 patents)

4.  Richard Woods (3 out of 5 patents)

5.  Ulrike Von Der Bey (3 out of 3 patents)

6.  Simon Brack (3 out of 3 patents)

7.  Sarah Batey (3 out of 3 patents)

8.  Michela Silacci Melkko (2 out of 3 patents)

9.  Fabian Buller (2 out of 2 patents)

10.  Ulrich Wüllner (2 out of 2 patents)

11.  Irene Zbinden (2 out of 2 patents)

12.  Isabella Attinger-Toller (2 out of 3 patents)

13.  Susann König-Friedrich (2 out of 2 patents)

14.  Frédéric Mourlane (2 out of 2 patents)

15.  Barbara Zubler (1 out of 2 patents)


7 patents:

Company Overview
Covagen AG is a biotechnology company focused on the discovery and development of novel bispecific protein therapeutics for the treatment of cancer and immune-related diseases. The company's proprietary platform allows for the rapid and efficient generation of bispecific antibodies with improved therapeutic properties. Covagen's innovative approach has the potential to revolutionize the treatment of various diseases by targeting multiple pathways simultaneously.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

7 Patents

#71 in Zug

#1,339 in Switzerland

Zug, CH
Zug, Switzerland
Forward Citations = 9

31 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Covagen Ag. Retrieved from https://idiyas.com/company/covagen-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…